In melanoma patients, peritumoral injection of IFN-β also recruits effector cells, including CD8 and TIA1-positive cytotoxic T cells (CTLs), into the tumor microenvironment [11], which suggests a possible mechanism for the therapeutic effects of IFN-β in the treatment of melanoma. The gene discussed is TIA1; the disease is melanoma.